Efficacy and safety of Elobixibat as a preparation for colonoscopy: a single-center, open-label, randomized controlled exploratory trial (none)

未提供0 个研究点目标入组 200 人开始时间: 待定最近更新: 2022年3月31日

适应症

试验速览

暂无简介。

•(1) Patients capable of taking oral bowel cleansers who are undergoing colonoscopy.
•(2) Patients over 20 years of age at the time of obtaining consent.
•(3) Patients who take an oral bowel cleanser in the hospital.
•(4) Patients with written consent to participate in this study.
•(5) Patients who are able to walk independently and respond to questionnaires and other surveys.

•(1) Patients with advanced colorectal cancer, extramural compression due to intra-abdominal tumors, Crohn's disease, ischemic colitis, and bowel obstruction.
•(2) Patients with previous colorectal resection.
•(3) Patients with extremely poor general health, NYHA cardiac function classifications III and IV with severe cardiac disease and renal disease with eGFR<
•(4) Patients with significant electrolyte abnormalities with a serum Na concentration of less than 135 mEq/L, 148 mEq/L or greater, or a serum K concentration of less than 3.5 mEq/L or greater than 5.0 mEq/L.
•(5) Patients with a history of hypersensitivity to the components of Goofice tablets (elobixibat).
•(6) Patients who do not undergo total colorectal observation.
•(7) Patients who participated in a drug or other clinical trial at the same time as the study or within 30 days prior to inclusion in the study.
•(8) Patients taking Goofice tablets (elobixibat).
•(9) Patients who are pregnant, lactating, or who may be pregnant.
•(10) Other patients who are deemed unsuitable for inclusion in the subject by the physician.
•(11) Patients on the Bristol Stool Form Scale 1 or 2.

Bowel Cleanliness (BBPS)

发起方

未提供